Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to ...
Pasithea Therapeutics announced promising preclinical data for PAS-004, a next-generation MEK inhibitor, which shows superior effectiveness in inhibiting the ETS2 pathway associated with ...
Nearly a fifth of patients with cancer being treated with mitogen-activated protein kinase (MEK) inhibitors in clinical trials developed an ocular adverse event, according to a research letter ...
This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...
Bottom line: The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II ...
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma The following represents disclosure information ...
Discover IMRX’s innovative cancer drug atebimetinib and upcoming milestones. Learn about trial results, financial outlook, ...
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback